ALSO NOTED: Takeda prevails in Actos patent suit; Analyst gets peek at Biovail founder's laptop;

> The U.S. Supreme court refused to reconsider an appeals court ruling that upheld Takeda's patent on its diabetes treatment Actos, a decision that keeps Alphapharm from launching a generic version until 2011. Report

> A former Bank of America analyst who's suing Biovail for defamation is getting access to founder Eugene Melnyk's computer to search for deleted emails. Report

> Taro Pharmaceutical got the tentative nod from the FDA for its copycat form of GlaxoSmithKline's Lamictal (generically lamotrigine), an anti-seizure med also used as a mood stabilizer. Release

> Sinclair Pharma disclosed that non-executive director JeanCharles Tschudin bought 55,000 shares on top of the 20,000 he purchased last week. Report

> Amgen got a badly needed boost with its announcement that its most promising experimental therapy, denosumab, significantly increased bone mineral density in a Phase III trial. Report

> A new report out says that the clinical trial process routinely ignores women, the elderly, minorities, the disabled and people living in rural America. Report

> The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. Report

> Do VC groups love the Web more than biotech? Report

Most popular this week: FDA issues early-warning trifecta. Report

And Finally... Birds do it--select fruits with the highest concentrations of antioxidants, that is. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.